Patent US5501983A successfully refreshed from Google Patents.
US5501983A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Assay of free and complexed prostate-specific antigen
Assignee: Individual
•
Filing: 1991-07-22
•
Granted: 1996-03-26
•
Expires: 2011-07-22
Abstract
Abstract PCT No. PCT/FI91/00223 Sec. 371 Date Mar. 19, 1993 Sec. 102(e) Date Mar. 19, 1993 PCT Filed Jul. 22, 1991 PCT Pub. No. WO92/01936 PCT Pub. Date Jun. 2, 1992.According to the method of the invention, immunoassays are applied to measure free PSA as well as a proteinase inhibitor complex. Free PSA and PSA complex are according to the invention measured by a non-competitive immunoassay employing at least two different antibodies. The invention is further characterized in that the PSA proteinase inhibitor complex of interest is formed with alpha 1-antichymotrypsin. Moreover, the invention is characterized in that free PSA, the PSA-proteinase inhibitor complex and their ratio are applied in the diagnosis of patients with prostate cancer.
Inventors
- 👤 Hans Lilja
- 👤 Ulf-Hakan Stenman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 16:10
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/573; G01N33/575; G01N33/57525
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
27 words
An immunoassay of prostate-specific antigen (PSA) characterized in that the fraction of prostate-specific antigen in complex with α 1 -antichymotrypsin is measured using one or more antibodies.
Claim 2
Dependent Claim
27 words
An immunoassay of prostate-specific antigen (PSA) characterized in that the fraction of prostate-specific antigen in complex with α 1 -antichymotrypsin is measured using one or more antibodies.
Claim 3
Dependent Claim
26 words
An immunoassay according to claim 1 characterized in that the fraction of prostate-specific antigen in complex with α 1 -antichymotrypsin is measured by a non-competitive immunoassay.
Claim 4
Dependent Claim
32 words
An immunoassay according to claim 2 characterized in that the fraction of prostate-specific antigen in complex with α 1 -antichymotrypsin is measured by a non-competitive immunoassay employing at least two different antibodies.
Claim 5
Dependent Claim
34 words
An immunoassay according to claim 3 characterized in that the antibodies used for the recognition of the PSA-α 1 -antichymotrypsin complex bind either to the PSA-α 1 -antichymotrypsin complex or to α 1 -antichymotrypsin.
Claim 6
Dependent Claim
47 words
An immunoassay method for determining the amount of free noncomplexed prostate specific antigens in a sample comprising the steps of exposing the sample to antibodies specific to the free non-complexed prostate-specific antigens, and detecting the amount of antibodies which are bound to the free non-complexed prostate-specific antigens.
Claim 7
Dependent Claim
47 words
An immunoassay method for determining the amount of free noncomplexed prostate specific antigens in a sample comprising the steps of exposing the sample to antibodies specific to the free non-complexed prostate-specific antigens, and detecting the amount of antibodies which are bound to the free non-complexed prostate-specific antigens.
Claim 8
Dependent Claim
22 words
An immunoassay according to claim 5 characterized in that the amount of free non-complexed prostate-specific antigen is measured by a non-competitive immunoassay.
Claim 9
Dependent Claim
28 words
An immunoassay according to claim 6 characterized in that the amount of free non-complexed prostate-specific antigen is measured by a non-competitive immunoassay employing at least two different antibodies.
Claim 10
Dependent Claim
54 words
An immunoassay according to claim 7 characterized in that the antibodies used for recognition of free non-complexed prostate-specific antigen (free PSA) bind to prostate specific antigen, and that at least one of the epitopes defined by the antibodies is not exposed (available) when the prostate specific antigen is in complex with α 1 -antichymotrypsin.
Claim 11
Dependent Claim
51 words
An immunoassay of prostate-specific antigen (PSA) characterized in that the ratio between a) the fraction of free non-complexed prostate-specific antigen and b) the fraction of prostate-specific antigen in complex with α 1 -antichymotrypsin is measured using one or more antibodies that makes it possible to discriminate between free and complexed PSA.
Claim 12
Dependent Claim
51 words
An immunoassay of prostate-specific antigen (PSA) characterized in that the ratio between a) the fraction of free non-complexed prostate-specific antigen and b) the fraction of prostate-specific antigen in complex with α 1 -antichymotrypsin is measured using one or more antibodies that makes it possible to discriminate between free and complexed PSA.
Claim 13
Dependent Claim
40 words
An immunoassay according to claim 9 characterized in that the ratio between a) the fraction of free non-complexed prostate-specific antigen and b) the fraction of the prostate-specific antigen in complex with α 1 -antichymotrypsin is measured by a non-competitive immunoassay.
Claim 14
Dependent Claim
46 words
An immunoassay according to claim 10 characterized in that the ratio between a) the fraction of free non-complexed prostate-specific antigen and b) the fraction of the prostate-specific antigen in complex with α 1 -antichymotrypsin is measured by a non-competitive immunoassay employing at least three different antibodies.
Claim 15
Dependent Claim
34 words
An immunoassay according to claim 11 characterized in that the antibodies used for the recognition of the PSA-α 1 -antichymotrypsin complex bind either to the PSA-α 1 -antichymotrypsin complex or to α 1 -antichymotrypsin.
Claim 16
Dependent Claim
32 words
An immunoassay of prostate-specific antigen (PSA) characterized in that the ratio between a) the fraction of prostate-specific antigen complexed with α 1 -antichymotrypsin and b) immunologically recognized total prostate-specific antigen is measured.
Claim 17
Dependent Claim
32 words
An immunoassay of prostate-specific antigen (PSA) characterized in that the ratio between a) the fraction of prostate-specific antigen complexed with α 1 -antichymotrypsin and b) immunologically recognized total prostate-specific antigen is measured.
Claim 18
Dependent Claim
29 words
An immunoassay of prostate-specific antigen (PSA) characterized in that the ratio between a) the fraction of free non-complexed prostate-specific antigen and b) immunologically recognized total prostate-specific antigen is measured.
Claim 19
Dependent Claim
29 words
An immunoassay of prostate-specific antigen (PSA) characterized in that the ratio between a) the fraction of free non-complexed prostate-specific antigen and b) immunologically recognized total prostate-specific antigen is measured.
Claim 20
Independent Claim
26 words
A method for differentiation between benign prostatic hyperplasia and prostate cancer by determining the ratio between free PSA: immunologically recognized total PSA in a patient's serum.
Claim 21
Independent Claim
26 words
A method for differentiation between benign prostatic hyperplasia and prostate cancer by determining the ratio between free PSA: immunologically recognized total PSA in a patient's serum.
Claim 22
Independent Claim
21 words
A method for screening prostate cancer by determining the ratio between free PSA: immunologically recognized total PSA in a patient's serum.
Claim 23
Independent Claim
21 words
A method for screening prostate cancer by determining the ratio between free PSA: immunologically recognized total PSA in a patient's serum.
Claim 24
Independent Claim
27 words
A method for differentiation between benign prostatic hyperplasia and prostate cancer by determining the ratio between free PSA:PSA complexed with α 1 -antichymotrypsin in a patient's serum.
Claim 25
Independent Claim
27 words
A method for differentiation between benign prostatic hyperplasia and prostate cancer by determining the ratio between free PSA:PSA complexed with α 1 -antichymotrypsin in a patient's serum.
Claim 26
Independent Claim
22 words
A method for screening prostate cancer by determining the ratio between free PSA:PSA complexed with α 1 -antichymotrypsin in a patient's serum.
Claim 27
Independent Claim
22 words
A method for screening prostate cancer by determining the ratio between free PSA:PSA complexed with α 1 -antichymotrypsin in a patient's serum.
Claim 28
Independent Claim
30 words
A method for differentiation between benign prostatic hyperplasia and prostate cancer by determining the ratio between PSA complexed with α 1 -antichymotrypsin: immunologically recognized total PSA in a patient's serum.
Claim 29
Independent Claim
30 words
A method for differentiation between benign prostatic hyperplasia and prostate cancer by determining the ratio between PSA complexed with α 1 -antichymotrypsin: immunologically recognized total PSA in a patient's serum.
Claim 30
Independent Claim
25 words
A method for screening prostate cancer by determining the ratio between PSA complexed with α 1 -antichymotrypsin: immunologically recognized total PSA in a patient's serum.
Claim 31
Independent Claim
25 words
A method for screening prostate cancer by determining the ratio between PSA complexed with α 1 -antichymotrypsin: immunologically recognized total PSA in a patient's serum.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-03-26 | 1999-09-25 | 2000-03-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-03-26 | 2003-09-25 | 2004-03-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-03-26 | 2007-09-25 | 2008-03-26 | $7700.00 | Window Closed / Lapsed |